Cadrenal Therapeutics (CVKD)

Executive Summary

Cadrenal Therapeutics is a late-stage biopharmaceutical company focused on developing novel therapies for life-threatening immune and thrombotic conditions. Its pipeline is anchored by three key assets: CAD-1005, a first-in-class 12-LOX inhibitor for heparin-induced thrombocytopenia (HIT); tecarfarin, a Phase 3-ready vitamin K antagonist for high-risk cardiovascular patients requiring stable anticoagulation; and frunexian, a clinical-stage Factor XIa inhibitor for acute hospital care. The company's strategic focus on addressing unmet medical needs in thrombosis and hematology positions it for significant value creation as it advances these programs toward regulatory milestones. With a market capitalization of approximately $18.8 million, Cadrenal offers a compelling risk-reward profile given the near-term potential of its pipeline. Tecarfarin, with its favorable pharmacokinetic profile and ongoing regulatory interactions, represents the most advanced asset and could drive near-term value. CAD-1005 addresses a critical unmet need in HIT, a condition with limited treatment options. Frunexian targets a broad market in hospital-based anticoagulation. Successful execution of clinical trials and potential partnerships could catalyze significant upside, though the company faces typical biotech risks including funding needs and clinical trial outcomes.

Upcoming Catalysts (preview)

• Q3 2026Tecarfarin Phase 3 Trial Initiation80% success
• H1 2027CAD-1005 Phase 2/3 Clinical Data Update60% success
• Q4 2026Frunexian Phase 1/2 Results or Partnership Announcement50% success